Entheon Announces Continuance into British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's an
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-10-08 6:49 PM EDT | Entheon Biomedical Corp.
TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group
Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)
Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol)
Québec et Vienne, Autriche--(Newsfile Corp. - 8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte. Autorisé par Sant
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-10-08 10:01 AM EDT | Breathe BioMedical Inc.
Illumisoft Appoints Former 3M Growth Ventures Leader Bill Weber as Chief Strategy Officer
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (OTCQB: FUVCF) ("Illumisoft" or the "Company") announces the appointment of Bill Weber as Chief Strategy Officer, effective October 7, 2026. Mr. Weber will work with Chief Executive Officer Ehsan Agahi and the leadership team on corporate strategy, commercial priorities, strategic partnerships and market development as Illumisoft advances commercialization of its SaniLume upper-room
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-10-08 9:27 AM EDT | Illumisoft Lighting Corp.
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 8, 2026) - Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme. The programme has demonstrated that BioHarvest's Botanical Synthesis™ platform is capable of producing the targeted ne
Biotechnology, Pharmaceuticals, Health
2026-10-08 8:00 AM EDT | BioHarvest Sciences Inc.
Zenith Epigenetics Receives FDA Clearance for Registration Enabling Study of ZEN-3694 in NUT Carcinoma
Calgary, Alberta--(Newsfile Corp. - October 8, 2026) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has received clearance from the US Food and Drug Administration ("FDA") to sponsor a registration enabling study for ZEN-3694, the Company's clinical oncology candidate, for the treatment of NUT carcinoma. Zenith and the FDA concur on the design of the randomized trial, which will compare the combination of ZEN-3694 and a CKD4/6 inhibitor to the best avai
2026-10-08 7:15 AM EDT | Zenith Capital Corp.
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Highlights Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer markets Supports commercialization strategy and strategic engagement with appliance manufacturers across America's premium refrigeration sector Patent term extends through Octobe
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-08 3:05 AM EDT | TempraMed Technologies Ltd.
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Calgary, Alberta--(Newsfile Corp. - October 7, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that it has received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas (LARTA Board), including ethics approval from the LARTA Ethics Committee, for its commercial Phase 1 study of VesCell™as a treatment for angina, vascular dementia and pain. This milestone advances the Company's clinical developmen
Biotechnology, Pharmaceuticals, Health
2026-10-07 2:37 PM EDT | Hemostemix Inc.
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Grasonville, Maryland--(Newsfile Corp. - October 7, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health subsidiary, OSAH received feedback f
2026-10-07 8:30 AM EDT | OS Therapies
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Nova Scotia
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - October 7, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that the Breast Health Research Unit (BHRU) at IWK Health has joined as the second Canadian site in its large multi-center observational data collection study to advan
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-10-07 8:00 AM EDT | Breathe BioMedical Inc.
PharmaTher Launches M3DICINES(TM) National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company advancing 3D-printed medicines, today announced the launch of the M3DICINES™ National Network Program (the "Network Program"). The program will build a national network of qualified sites that make personalized medicines on CraftMake™ pharmaceutical 3D printers, supported by PharmaTher's M3DICINES&#
Biotechnology, Pharmaceuticals
2026-10-07 8:00 AM EDT | PharmaTher Holdings Ltd.
Palindrome Pharma Launches in Canada to Unlock Access to High-Quality Biosimilar Medicines
Toronto, Ontario--(Newsfile Corp. - October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system. As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and C
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-07 12:30 AM EDT | Palindrome Pharma Inc.
Microbiome Labs Unveils Enhanced Online Ordering Experience and Rebrand Shaped by Practitioner and Customer Feedback
Franklinton, North Carolina--(Newsfile Corp. - October 6, 2026) - Microbiome Labs™, a leader in spore-based probiotics and a division of Novonesis, announced the completion of a company-wide rebranding. Alongside this rebrand, the company launched a redesigned website and enhanced its online experience with capabilities that give practitioners a personalized way to provide education and recommend products directly to patients. These initiatives were unveiled to healthcare practitioners
2026-10-06 10:00 AM EDT | Microbiome Labs
Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the f
Biotechnology, Pharmaceuticals
2026-10-06 9:28 AM EDT | Okogen
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Grasonville, Maryland--(Newsfile Corp. - October 6, 2026) -
2026-10-06 8:30 AM EDT | OS Therapies
Izotropic Closes Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - October 6, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that further to its September 25th announcement it has com
2026-10-06 8:00 AM EDT | Izotropic Corporation
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-06 7:00 AM EDT | Phio Pharmaceuticals Corp.
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Biotechnology, Pharmaceuticals
2026-10-05 8:00 AM EDT | PharmaTher Holdings Ltd.